STOCK TITAN

DLA Piper advises Histogen in its US$14 million upsized public offering

Rhea-AI Impact
(Moderate)
Rhea-AI Sentiment
(Neutral)
Tags

NEW YORK, Jan. 7, 2021 /PRNewswire/ -- DLA Piper represented advised Histogen, Inc. (NASDAQ: HSTO), a clinical-stage therapeutics company focused on developing potential first-in-class therapeutics that ignite the body's natural process to repair and maintain healthy biological function, in its public offering of 11,600,000 shares of common stock, pre-funded warrants to purchase up to 2,400,000 shares of common stock and warrants to purchase up to an aggregate of 14,000,000 shares of common stock at a price of $1.00 per share.

"We were pleased to bring our extensive experience helping life sciences companies access the capital markets to close this transaction. This funding will allow Histogen to expand its research and development efforts as it continues to advance innovative therapeutic solutions," said Larry Nishnick, the DLA Piper partner who led the firm's deal team.

In addition to Nishnick (San Diego), the DLA Piper team advising Histogen included partner Patrick O'Malley (San Diego) and associate Kathryn Fortin (San Diego).

DLA Piper's global capital markets team represents issuers and underwriters in registered and unregistered equity, equity-linked and debt capital markets transactions, including initial public offerings, follow-on equity offerings, equity-linked securities offerings, and offerings of investments grade and high-yield debt securities.

DLA Piper advises on all aspects of the life sciences sector, combining subject matter experience with considerable knowledge of the scientific, medical, regulatory, commercial and enforcement environments facing biopharmaceutical, medical device, research and diagnostics clients. Recognizing that clients' needs vary, the firm rapidly organizes and customizes client service teams, whether for a large pharmaceutical company, a mid-sized medical device client or a development-stage biotech company. 

About DLA Piper
DLA Piper is a global law firm with lawyers located in more than 40 countries throughout the Americas, Europe, the Middle East, Africa and Asia Pacific, positioning us to help clients with their legal needs around the world. In certain jurisdictions, this information may be considered attorney advertising. dlapiper.com

 

Cision View original content:http://www.prnewswire.com/news-releases/dla-piper-advises-histogen-in-its-us14-million-upsized-public-offering-301202841.html

SOURCE DLA Piper

HISTOGEN INC

OTC:HSTO

HSTO Rankings

HSTO Latest News

HSTO Stock Data

2.14M
3.93M
2.85%
5.25%
1.57%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States of America
San Diego

About HSTO

a regenerative medicine company based on naturally-produced products from newborn fibroblasts grown in a proprietary bioreactor. two product families - a proprietary liquid complex of embryonic-like proteins and growth factors, and a human extracellular matrix (ecm) material, exceltrix.